Eikon Therapeutics advanced IPO plans with public filings indicating a multi‑hundred‑million dollar raise to fund its oncology‑focused pipeline anchored by Chinese cancer assets. The company set offering ranges and registration terms that would generate proceeds to accelerate clinical programs and broaden its R&D platform, according to prospectus filings. Eikon’s move comes amid renewed investor appetite for drug‑discovery platforms and computationally driven biotech. The IPO terms and prospectus emphasize the company’s technology and China partnerships as core value drivers, while also exposing Eikon to public‑market scrutiny on clinical proof‑points and commercialization timelines.